CMS advises Carlyle on acquisition of Baxter International’s Kidney Care
An international CMS team has advised global investment & private equity firm Carlyle on the acquisition of Vantive, the division of Baxter Group focused on renal & kidney healthcare (Baxter International’s Kidney Care unit), for a reported value of USD 3.8bn. The transaction is expected to close in late 2024 or early 2025, subject to customary regulatory approvals.
CMS advised Carlyle on a number of areas in connection with the acquisition including corporate, employment, pensions, real estate, intellectual property and healthcare regulatory aspects. Carlyle has been a private equity investor in the medical technology sector over the past decade, with investments totalling over USD 40bn in enterprise value. As part of the acquisition, the kidney care unit will be renamed to Vantive.
CMS international team was led by London corporate partner Jason Zemmel, with his associates Charlotte Harding-Carroll and Raghav Vohora. The Spanish team was led and coordinated by corporate partner, Ignacio Cerrato.
